A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Henagliflozin on Myocardial Fibrosis Burden in Patients With Non-Obstructive Hypertrophic Cardiomyopathy Using 68Ga/18F-FAPI PET/CMR
Latest Information Update: 25 Dec 2025
At a glance
- Drugs Henagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
Most Recent Events
- 25 Dec 2025 New trial record